PCA3 and cancer: Ultimately, to accurately identify insignificant cancer we will need to look beyond histopathology in isolation, integrating biopsy data with the high-resolution 3D mapping and functional information derived from mpMRI and possibly that from biomarkers (PCA3, pro-2 PSA, and TMPRSS2:erg), mitochondrial RNA mapping (e.g., PC Mitomics Test), epigenetic DNA mapping (e.g., MDx Link), and other emerging predictors of the biologic behaviour of PC in an individualised way [24–28].